Nothing Special   »   [go: up one dir, main page]

MA32798B1 - Acides naphtylacétiques - Google Patents

Acides naphtylacétiques

Info

Publication number
MA32798B1
MA32798B1 MA33847A MA33847A MA32798B1 MA 32798 B1 MA32798 B1 MA 32798B1 MA 33847 A MA33847 A MA 33847A MA 33847 A MA33847 A MA 33847A MA 32798 B1 MA32798 B1 MA 32798B1
Authority
MA
Morocco
Prior art keywords
compounds
formula
naftilacetic
acids
invention concerns
Prior art date
Application number
MA33847A
Other languages
Arabic (ar)
English (en)
Inventor
Fariborz Firooznia
Paul Gillespie
Yun He
Li Chen
Tai-An Lin
Eric Mertz
Sung-Sau So
Hongying Yun
Zhenshan Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32798B1 publication Critical patent/MA32798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LES COMPOSÉS DE FORMULE I, AINSI QUE LEURS SELS ET ESTERS DE QUALITÉ PHARMACEUTIQUE, OÙ W, X, Y ET R1-R7 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION DÉTAILLÉE ET DANS LES REVENDICATIONS. DE PLUS, LA PRÉSENTE INVENTION CONCERNE DES MÉTHODES DE FABRICATION ET D'EMPLOI DES COMPOSÉS DE FORMULE I AINSI QUE DES COMPOSITIONS PHARMACEUTIQUES CONTENANT DE TELS COMPOSÉS. LES COMPOSÉS DE FORMULE I SONT DES ANTAGONISTES OU DES AGONISTES PARTIELS DU RÉCEPTEUR CRTH2 ET PEUVENT ÊTRE EMPLOYÉS DANS LE TRAITEMENT DE PATHOLOGIES ET DE TROUBLES ASSOCIÉS À CE RÉCEPTEUR, COMME L'ASTHME.
MA33847A 2008-11-17 2011-05-16 Acides naphtylacétiques MA32798B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11513308P 2008-11-17 2008-11-17
US22218209P 2009-07-01 2009-07-01
PCT/EP2009/064810 WO2010055004A1 (fr) 2008-11-17 2009-11-09 Acides naphtylacétiques

Publications (1)

Publication Number Publication Date
MA32798B1 true MA32798B1 (fr) 2011-11-01

Family

ID=41467025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33847A MA32798B1 (fr) 2008-11-17 2011-05-16 Acides naphtylacétiques

Country Status (30)

Country Link
US (1) US8642629B2 (fr)
EP (1) EP2346819B1 (fr)
JP (1) JP5463365B2 (fr)
KR (1) KR101322496B1 (fr)
CN (1) CN102216265B (fr)
AR (1) AR074352A1 (fr)
AU (1) AU2009315712A1 (fr)
BR (1) BRPI0921038A2 (fr)
CA (1) CA2740863A1 (fr)
CO (1) CO6351778A2 (fr)
CR (1) CR20110219A (fr)
CY (1) CY1114200T1 (fr)
DK (1) DK2346819T3 (fr)
EC (1) ECSP11011057A (fr)
ES (1) ES2408963T3 (fr)
HK (1) HK1162461A1 (fr)
HR (1) HRP20130613T1 (fr)
IL (1) IL212077A0 (fr)
MA (1) MA32798B1 (fr)
MX (1) MX2011005120A (fr)
NZ (1) NZ591914A (fr)
PE (1) PE20110703A1 (fr)
PL (1) PL2346819T3 (fr)
PT (1) PT2346819E (fr)
RS (1) RS52809B (fr)
RU (1) RU2539185C2 (fr)
SG (1) SG171734A1 (fr)
TW (1) TWI377197B (fr)
WO (1) WO2010055004A1 (fr)
ZA (1) ZA201102524B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2730390A1 (fr) 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Acides aminotetrahydroindazoloacetiques
JP5394487B2 (ja) 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
US8124629B2 (en) 2008-11-17 2012-02-28 Hoffmann-La Roche Inc. Naphthylacetic acids
CA2739725A1 (fr) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2
WO2012004722A1 (fr) 2010-07-05 2012-01-12 Actelion Pharmaceuticals Ltd Dérivés d'hétérocyclyle substitués par un 1-phényle et leur utilisation en tant que modulateurs des récepteurs de la prostaglandine d2
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US8691993B2 (en) * 2011-12-12 2014-04-08 Hoffmann-La Roche Inc. Piperidinyl naphthylacetic acids
WO2013093842A1 (fr) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Dérivés hétérocyclyle et leur utilisation comme modulateurs de récepteurs de la prostaglandine d2
US9000044B2 (en) * 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
CN108040481B (zh) 2015-04-24 2020-10-30 先正达参股股份有限公司 具有硫取代的五元环杂环的杀有害生物活性多环衍生物
US12091708B2 (en) 2017-01-09 2024-09-17 The Children's Hospital Of Philadelphia Compositions and methods targeting the Th2 pathway for the treatment of asthma
WO2023165874A1 (fr) * 2022-03-01 2023-09-07 Syngenta Crop Protection Ag Composés herbicides à base de pyrimidinyl-oxy-quinoléine

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3899529A (en) * 1973-02-22 1975-08-12 Merck & Co Inc Aroyl substituted naphthalene acetic acids
US4443462A (en) 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
US4371537A (en) * 1981-08-13 1983-02-01 The Dow Chemical Company Sulfur-substituted phenoxypyridines having antiviral activity
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE3623941A1 (de) * 1986-07-16 1988-01-28 Bayer Ag Substituierte amino-5,6,7,8-tetrahydronaphthyl-oxyessigsaeuren, verfahren zu deren herstellung sowie die verwendung als arzneimittel
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
DE4235155A1 (de) * 1992-10-19 1994-04-21 Basf Ag Verfahren zur Herstellung von Methylsulfonylbenzoesäuren
JP2562405B2 (ja) 1993-04-06 1996-12-11 花王株式会社 ケラチン繊維処理剤組成物
ES2118333T3 (es) 1993-12-09 1998-09-16 Ono Pharmaceutical Co Derivados del acido naftilacetico como agonistas y antagonistas de pgez.
GB9516788D0 (en) 1995-08-16 1995-10-18 Agrevo Uk Ltd Fungicides
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
ATE388708T1 (de) * 2003-06-20 2008-03-15 Amgen Inc Piperazinderivate und anwendungsverfahren
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2007508363A (ja) 2003-10-14 2007-04-05 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7226951B2 (en) * 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
EP1814865A4 (fr) * 2004-09-21 2009-09-02 Wyeth Corp Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
AU2005289881A1 (en) 2004-09-23 2006-04-06 Amgen Inc. Substituted sulfonamidopropionamides and methods of use
CA2580621A1 (fr) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd Nouveaux antibiotiques bicycliques
RU2388748C2 (ru) * 2004-12-21 2010-05-10 Ф. Хоффманн-Ля Рош Аг Производные тетралина и индана и их применения в качестве антагонистов 5-нт
KR20070114762A (ko) 2005-02-24 2007-12-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질환 치료를 위한 ｐｇｄ2 수용체 길항제
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5249031B2 (ja) 2005-09-01 2013-07-31 イーライ リリー アンド カンパニー ５−ＨＴ２Ｃ受容体アゴニストとしての６−Ｎ結合型へテロ環置換された２，３，４，５−テトラヒドロ−１Ｈ−ベンゾ［ｄ］アゼピン
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
CA2621310C (fr) * 2005-09-27 2014-08-12 Shionogi & Co., Ltd. Derive sulfonamide ayant une activite antagoniste de recepteur pgd2
US8211908B2 (en) 2006-05-26 2012-07-03 Toyama Chemical Co., Ltd. Heterocyclic compound or salt thereof and intermediate thereof
AU2007258527A1 (en) 2006-06-12 2007-12-21 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
EP2066628B1 (fr) * 2006-07-25 2010-10-20 Sanofi-Aventis 2-phényl-indoles en tant qu'antagonistes du récepteur de la prostaglandine d2
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CA2730390A1 (fr) * 2008-07-15 2010-01-21 F.Hoffmann-La Roche Ag Acides aminotetrahydroindazoloacetiques
JP5394487B2 (ja) * 2008-07-15 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー アミノテトラヒドロインダゾロ酢酸
EP2321268A2 (fr) * 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryle aminotétralines
EP2321267A2 (fr) * 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Monoaryle aminotétralines
WO2010018109A2 (fr) * 2008-08-15 2010-02-18 F. Hoffmann-La Roche Ag Aminotétralines substituées
CA2739725A1 (fr) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Acides naphtylacetiques employes en tant qu'antagonistes ou agonistes partiels de crth2
US8124629B2 (en) * 2008-11-17 2012-02-28 Hoffmann-La Roche Inc. Naphthylacetic acids

Also Published As

Publication number Publication date
NZ591914A (en) 2013-04-26
EP2346819B1 (fr) 2013-04-10
RS52809B (en) 2013-10-31
SG171734A1 (en) 2011-07-28
IL212077A0 (en) 2011-06-30
TW201022207A (en) 2010-06-16
CR20110219A (es) 2011-08-24
CN102216265B (zh) 2014-04-30
CO6351778A2 (es) 2011-12-20
EP2346819A1 (fr) 2011-07-27
ECSP11011057A (es) 2011-10-31
DK2346819T3 (da) 2013-05-13
CA2740863A1 (fr) 2010-05-20
CN102216265A (zh) 2011-10-12
US8642629B2 (en) 2014-02-04
AU2009315712A1 (en) 2010-05-20
WO2010055004A1 (fr) 2010-05-20
CY1114200T1 (el) 2016-08-31
AR074352A1 (es) 2011-01-12
TWI377197B (en) 2012-11-21
MX2011005120A (es) 2011-05-30
ZA201102524B (en) 2014-09-25
JP5463365B2 (ja) 2014-04-09
HRP20130613T1 (en) 2013-07-31
JP2012508714A (ja) 2012-04-12
PT2346819E (pt) 2013-05-10
PL2346819T3 (pl) 2013-09-30
BRPI0921038A2 (pt) 2019-09-24
KR101322496B1 (ko) 2013-10-29
ES2408963T3 (es) 2013-06-24
RU2011124150A (ru) 2012-12-27
HK1162461A1 (en) 2012-08-31
KR20110071121A (ko) 2011-06-28
US20100125058A1 (en) 2010-05-20
RU2539185C2 (ru) 2015-01-20
PE20110703A1 (es) 2011-10-13

Similar Documents

Publication Publication Date Title
MA32798B1 (fr) Acides naphtylacétiques
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
MA33053B1 (fr) Inhibiteurs de la poly(adp-ribose) polymerase (parp)
TN2009000138A1 (fr) Biaryl-ether-urees
MA31373B1 (fr) Composes amino-heterocycliques
MA35285B1 (fr) Indazoles
MA31339B1 (fr) Dérivés hétérobicycliques de pyrazole et méthodes d'utilisation
MA30406B1 (fr) Nouveaux composes
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
TN2012000192A1 (fr) N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA30694B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane